1,044
Participants
Start Date
September 30, 2011
Primary Completion Date
January 31, 2016
Study Completion Date
January 31, 2016
OPC-34712
"Phase A: 1-2 mgs/day by mouth, max of 4 wks.~Phase B: 1-4 mgs/day by mouth, up to 52 weeks"
Taipei
New Taipei City
Taoyuan
Kashsiung
Manila
Cebu City
Davao City
Zagreb
Staten Island
Staten Island
Belgrade
Jamaica
Cedarhurst
Chernihiv
Buffalo
Rochester
Kota Bharu
Allentown
Norristown
Washington D.C.
Novi Sad
Vinnytsia
Diyarbakır
Richmond
Novi Kneževac
Charleston
Jalan Greentown
Ipoh
Maitland
Miami
North Miami
Miami Springs
Tampa
Kragujevac
Bradenton
Leesburg
Birmingham
Memphis
Flowood
Kocaeli
Kajang
Dayton
Dnipropetrovsk
Dnipropetrovsk
Rijeka
Kuala Lumpur
Hoffman Estates
Joliet
Oak Brook
Chicago
Kharkiv
St Louis
St Louis
Saint Charles
Monterrey
Odesa
Overland Park
Lake Charles
Shreveport
Little Rock
Little Rock
Springdale
Kherson, Vil. Stepanivka
Dallas
Dallas
Houston
San Luis Potosí City
Austin
Austin
Lviv
Bratislava
Sabak Bernam
Las Vegas
Torrance
Pico Rivera
Cerritos
Long Beach
Glendale
National City
Escondido
Oceanside
San Diego
San Diego
San Diego
Anaheim
Garden Grove
Oakland
Simferopol
Rimavská Sobota
Kirkland
Piteşti
Moscow
Moscow
Târgovişte
Moscow Region
Arkhangelsk
Petrozavodsk
Village Nikolskoe
Saint Petersburg
Saint Petersburg
Saint Petersburg
Saint Petersburg
Saint Petersburg
Craiova
Arad
Cluj-Napoca
Saratov
Samara
Brasov
Nizhny Novgorod
Focşani
Tomsk
Iași
Burlington
Chatham
Barranquilla
Bello
Bogotá
Pereira
Fujisawa-shi
Kumamoto
Kunigami-gun
Sakai-shi
Daugavpils
Jelgava
Liepāja
Riga
Strenči
Col. Florida
Choroszcz
Gdansk
Gdansk
Lodz
San Juan
San Juan
Bucharest
Bucharest
Bucharest
Michalovce
Rožňava
Incheon
Incheon
Seoul
Seoul
Seoul
Hlevakha
Kyiv
Kyiv
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY